Fingerprint
Dive into the research topics of 'Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
James Chih Hsin Yang, Jin Yuan Shih, Wu Chou Su, Te Chun Hsia, Chun Ming Tsai, Sai Hong Ignatius Ou, Chung Jen Yu, Gee Chen Chang, Ching Liang Ho, Lecia V. Sequist, Arkadiusz Z. Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, Pan Chyr Yang, Vincent A. Miller
Research output: Contribution to journal › Article › peer-review
385
Scopus
citations